|
Originally published In Press as doi:10.1074/jbc.M201283200 on June 26, 2002
J. Biol. Chem., Vol. 277, Issue 36, 32970-32977, September 6, 2002
Syndecan-4 Modulates Focal Adhesion Kinase Phosphorylation*
Sarah A.
Wilcox-Adelman ,
Fabienne
Denhez, and
Paul F.
Goetinck§
From the Cutaneous Biology Research Center, Massachusetts General
Hospital, Harvard Medical School,
Charlestown, Massachusetts 02129
Received for publication, February 7, 2002, and in revised form, June 25, 2002
 |
ABSTRACT |
The cell-surface heparan sulfate
proteoglycan syndecan-4 acts in conjunction with the
5 1 integrin to promote the
formation of actin stress fibers and focal adhesions in fibronectin
(FN)-adherent cells. Fibroblasts seeded onto the cell-binding domain
(CBD) fragment of FN attach but do not fully spread or form focal
adhesions. Activation of Rho, with lysophosphatidic acid (LPA), or
protein kinase C, using the phorbol ester phorbol 12-myristate
13-acetate, or clustering of syndecan-4 with antibodies directed
against its extracellular domain will stimulate formation of focal
adhesions and stress fibers in CBD-adherent fibroblasts. The distinct
morphological differences between the cells adherent to the CBD and to
full-length FN suggest that syndecan-4 may influence the organization
of the focal adhesion or the activation state of the proteins that
comprise it. FN-null fibroblasts (which express syndecan-4) exhibit
reduced phosphorylation of focal adhesion kinase (FAK) tyrosine 397 (Tyr397) when adherent to CBD compared with FN-adherent
cells. Treating the CBD-adherent fibroblasts with LPA, to activate Rho,
or the tyrosine phosphatase inhibitor sodium vanadate increased the
level of phosphorylation of Tyr397 to match that of
cells plated on FN. Treatment of the fibroblasts with PMA did not
elicit such an effect. To confirm that this regulatory pathway includes
syndecan-4 specifically, we examined fibroblasts derived from
syndecan-4-null mice. The phosphorylation levels of FAK
Tyr397 were lower in FN-adherent syndecan-4-null
fibroblasts compared with syndecan-4-wild type and these levels were
rescued by the addition of LPA or re-expression of syndecan-4. These
data indicate that syndecan-4 ligation regulates the phosphorylation of
FAK Tyr397 and that this mechanism is dependent on Rho but
not protein kinase C activation. In addition, the data suggest that
this pathway includes the negative regulation of a protein-tyrosine
phosphatase. Our results implicate syndecan-4 activation in a direct
role in focal adhesion regulation.
 |
INTRODUCTION |
Syndecan-4 is a member of a family of transmembrane heparan
sulfate proteoglycans (syndecans 1-4) that are characterized by divergent extracellular domains and short cytoplasmic domains that
contain two constant regions separated by a variable region that is
unique to each family member (reviewed in Refs. 1-4). Although all
members of the syndecan family arose from a single ancestral gene,
their expression patterns in tissues and during development are highly
regulated (3-5). The terminal four amino acids (EFYA) of the
cytoplasmic domain of all syndecan family members compose a binding
site for the PDZ-containing proteins: synbindin, syntenin, CASK/LIN-2,
and synectin (6-10). Unlike other family members, syndecan-4 binds
protein kinase C-
(PKC- )1 through the
intermediary phosphatidylinositol bisphosphate (11, 12) at the
variable region and the cytoplasmic protein syndesmos through both the
variable and the membrane-proximal constant regions (13). Syndecans-1,
-2, and -4 have been shown to bind extracellular matrix proteins
(14-16). However, syndecan-4 is the only family member to localize to
sites of cell-matrix adhesions (17). Comparison of the localization of
syndecan-4 with the focal adhesion marker protein vinculin suggests
that syndecan-4 does not localize to newly formed contacts but with
more established adhesion sites (18).
Focal adhesions are macromolecular complexes that localize to sites of
closest contact (10-15 nm) between cells and the underlying extracellular matrix substrate (reviewed in Refs. 19-21). Focal adhesions are composed of transmembrane receptors (primarily syndecan-4 and members of the integrin superfamily), structural molecules (such as
actin, talin, tensin, vinculin, and -actinin), and signaling molecules (i.e. focal adhesion kinase (FAK), PKC, and Src).
Focal adhesions, therefore, serve not only as structural supports but also as signaling conduits between the actin cytoskeleton and the
surrounding environment of the cell.
The generation of focal adhesions in fibronectin (FN)-adherent cells is
dependent on the ligation of two different transmembrane receptors:
integrins and syndecan-4. Fibroblasts seeded on the cell-binding domain
(CBD) of FN (which contains only the integrin-binding RGD sequence)
will attach but not form focal adhesions or actin stress fibers
(22-24). The addition of an antibody against the extracellular domain
of syndecan-4 stimulates focal adhesion and stress fiber formation in
cells plated on the CBD (24). The syndecan-4 signal can be bypassed in
CBD-adherent fibroblasts by directly stimulating the small GTPase Rho
with lysophosphatidic acid (LPA) (24). These data indicate that
syndecan-4 acts in cooperation with the
5 1 integrin to direct focal adhesion
formation and that the action of syndecan-4 is through a
Rho-dependent mechanism (24).
The generation of syndecan-4-null mice demonstrated no initial obvious
phenotype and showed, surprisingly, that cells seeded onto FN will form
stress fibers and focal adhesions in the absence of syndecan-4 (25,
26). These data point to another cell-surface heparan sulfate
proteoglycan that can compensate for the absence of syndecan-4.
Treatment of CBD-adherent syndecan-4-null fibroblasts with antibodies
to syndecan-4 do not form focal adhesions or stress fibers although
wild type fibroblasts do, suggesting that the syndecan-4 signaling
pathway can be selectively activated and does not function in the
syndecan-4-null cells (25). Interestingly, further studies have
documented that syndecan-4-null mice do not respond to physiological
insults as well as their wild type counterparts implying that
syndecan-4 may be important in combating "stress situations"
(26-28). Syndecan-4-null mice exhibit a delay in wound healing and
this deficiency appears to be due to an impairment in cell migration
that can also be demonstrated in in vitro migration assays
(26). Impaired cell migration may be because of the inability of cells
to either generate enough force to propel themselves over an underlying
substrate or to disengage established adhesion contacts to promote new
adhesions (29). Although many focal adhesion-associated proteins are
involved in cell migration, the tyrosine kinase FAK has been shown to
be intimately involved in focal adhesion turnover (30, 31). Loss of FAK
is associated with decreased cell migration and increased focal
adhesion size (30, 32-34), whereas overexpression of FAK increases
cell migration (34-36).
FAK serves as both a scaffolding and signaling protein in the focal
adhesion. A nonreceptor tyrosine kinase, FAK, is composed of a central
catalytic domain flanked by two noncatalytic regions (37). FAK contains
multiple tyrosine residues that, upon their phosphorylation, are
capable of binding proteins containing SH2 domains. Tyrosine 397 (Tyr397) is a critical phosphorylation site that results
from autophosphorylation upon antibody-induced clustering of
cell-surface integrins or cell adhesion to extracellular matrix
proteins (such as collagen, fibronectin, and vitronectin) (Refs. 38 and
39 and reviewed in Refs. 40 and 41). FAK-mediated cell migration is
dependent on phosphorylation of FAK Tyr397 (35). The
phosphorylated form of Tyr397 binds Src (38), the p85
subunit of phosphatidylinositol 3-kinase (42), phospholipase C 1
(43), the adaptor proteins Grb7 (44) and Shc (45), and the phosphatase
PTEN (46). The unlikely possibility that all of these proteins bind FAK
simultaneously suggests that distinct FAK-containing signaling
complexes probably exist within the focal adhesion (47). The
phosphorylation of the remaining tyrosine residues (407, 576, 577, 861, and 925) occurs in a Src-dependent manner (48-51).
Phosphotyrosines 576 and 577 are required for maximal FAK kinase
activity (48) and phosphotyrosine 925 acts as a binding site for the
Grb2 adaptor protein leading to activation of the Ras pathway (50).
Fibroblasts treated with LPA, which directly stimulates the small
GTPase Rho, show increases in FAK phosphorylation and its subsequent
localization to focal adhesions (52-57). Closer examination of early
adhesion events documented initial FAK phosphorylation occurring in a
Rho-independent manner followed by Rho-mediated FAK phosphorylation
(58). Recently, Ren et al. (31) demonstrated that FAK-null
cells exhibit constitutive activation of Rho and this activity level is
inversely correlated with focal adhesion turnover. They reintroduced
FAK to the deficient cells and showed that Rho activity was restored to
normal levels. This suggests that FAK is responsible for the transient
inhibition of Rho during early cell spreading (31). All of these
studies indicate that reciprocal interactions may occur between FAK and
Rho to facilitate cell spreading and focal adhesion and stress fiber formation.
General FAK phosphorylation levels increase during early cell spreading
(59) but maximal phosphorylation requires both the integrin-binding and
heparin-binding domains of FN (60). As syndecan-4 binds the
heparin-binding domain of FN (61) and has been shown to act in a
Rho-dependent manner to influence focal adhesions and actin
stress fibers (24), we were interested in determining what effect
syndecan-4 signaling might have on the autophosphorylation site of FAK.
We now demonstrate that increased phosphorylation of FAK
Tyr397 is dependent on syndecan-4 ligation, and that the
syndecan-4 signal may be superseded by direct activation of Rho.
 |
MATERIALS AND METHODS |
Cell Culture--
Three types of cells were used in this study.
Fibronectin-null cells which express syndecan-4 (24) and fibroblasts
derived from newborn littermates that were either wild type (+/+) or
null ( / ) for the syndecan-4 core protein gene. These cells are
referred to as FN-null and syndecan-4-WT or syndecan-4-null,
respectively. All cell types were maintained in Dulbecco's modified
Eagle's medium (Invitrogen) supplemented with 10% fetal bovine
serum (Invitrogen). For experimental assays, 1.5 × 105 cells/100-mm tissue culture dish were seeded in serum
overnight and subsequently serum starved for 18 h. The cells were
washed three times with phosphate-buffered saline minus calcium
chloride and magnesium chloride (PBS, Invitrogen) containing 0.5 mM EDTA and lifted from the dishes with a 1:1 dilution of
PBS/EDTA and 0.25% trypsin/EDTA (Invitrogen). The tissue culture
plates and glass coverslips used for the experiments were coated with
either 30 µg/ml FN (BD Biosciences, San Jose, CA) or 10 µg/ml CBD
(Invitrogen) diluted in PBS overnight at 4 °C. The plates and
coverslips were then washed with PBS, blocked with 1% bovine serum
albumin for 60 min at room temperature, and given a final wash before
the cells were seeded. The fibroblasts were allowed to attach and spread for 3 h in serum-free Dulbecco's modified Eagle's medium. Following this incubation the cell medium was replaced with serum-free medium containing either 500 ng/ml LPA (Sigma), 250 nM
phorbol myristate acetate (PMA) (Sigma), 0.5 mM sodium
vanadate (Sigma), or medium alone for 30 (for the FN-null cells) or 60 min (for the syndecan-4-WT and syndecan-4-null cells). All experiments were done on cultures that were 50% confluent.
Transient Transfection--
Syndecan-4-null fibroblasts were
transiently transfected with the rat syndecan-4 cDNA cloned in
pcDNA3.1 Hygro (Invitrogen) or pcDNA3.1 Hygro alone using
LipofectAMINE 2000 (Invitrogen) according to the manufacturer's
protocol. Detection of protein expression was ascertained by
heparitinase I treating the transfected cell lysates following a
protocol by Rapraeger and Ott (62). Syndecan-4 was detected
using the MS-4-E polyclonal antibody (24).
Cell Harvesting and Western Blotting--
Fibroblasts were
placed on ice and washed twice with cold PBS containing calcium
chloride and magnesium chloride and 1 mM sodium vanadate.
The cells were lysed with an extraction buffer containing 25 mM -glycerolphosphate (pH 7.3), 10 mM EDTA,
2 mM EGTA, 0.1 M NaCl, 1% Triton X-100, 10 mM -mercaptoethanol, 0.2 mM sodium vanadate,
1 mM benzamidine, 0.1 mM phenymethylsulfonyl fluoride, 2 µg/ml leupeptin, 1 µM pepstatin A, and 1 µg/ml aprotinin (63). The lysates were centrifuged at 14,000 rpm for
20 min (4 °C) to remove insoluble material and protein concentration was determined. Equal protein concentrations were resolved on 12%
SDS-PAGE and transferred electrophoretically to polyvinylidene difluoride membranes. The membranes were blocked with 5% bovine serum
albumin for 2 h at room temperature and incubated with primary antibodies diluted in 1% bovine serum albumin overnight at 4 °C. The monoclonal phosphotyrosine antibody directly conjugated to horseradish peroxidase (clone PY20) was purchased from BD Transduction Laboratories (Lexington, KY). The polyclonal FAK and phosphospecific FAK Tyr397 antibodies were obtained from Upstate
Biotechnology Inc. (Lake Placid, NY) and the -actinin antibody was
purchased from Sigma. After washing the blots, secondary antibodies
conjugated to horseradish peroxidase were added for 60 min at room
temperature. The membranes were subsequently washed again and detection
of signal was obtained using the West Pico enhanced chemiluminescent
kit according to the manufacturer's instructions (Pierce). Figures are
representative results of experiments that were performed at least
three times.
Immunofluorescence Assay--
Syndecan-4-WT and syndecan-4-null
cells were seeded on glass coverslips at a concentration of 9,000 cells/well of a 24-well plate for 3 h in serum-free medium and
then incubated for an additional 60 min in the presence or absence of
500 ng/ml LPA or 250 nM PMA or an additional 2 h in
the presence or absence of 15 µg/ml C3 exotransferase (List
Biological Laboratories, Campbell, CA). The cells were fixed with 4%
formaldehyde for 15 min, permeabilized for 10 min with cold 0.5%
Triton X-100, and blocked with 2 mg/ml bovine serum albumin for 20 min
at room temperature. The cells were then incubated with a monoclonal
FAK antibody (clone 4.47, Upstate Biotechnology Inc.; 1:50) or
polyclonal phosphospecific FAK Tyr397 antibodies (Upstate
Biotechnology Inc.; 1:50) and a monoclonal vinculin antibody (clone
hVIN-1, Sigma; 1:400) diluted in 2 mg/ml bovine serum albumin for 60 min at 37 °C. For experiments in which the monoclonal antibodies to
FAK and vinculin were to be used, the vinculin antibody was directly
conjugated to fluorescein isothiocyanate using a protein labeling kit
(Pierce) and incubated with the cells subsequent to incubation of the
FAK primary antibody and the appropriate secondary antibody to prevent
cross-reactivity. All reagents and antibodies were diluted in Small's
buffer (64). The cells were washed for 60 min with Small's buffer and
then incubated with the corresponding secondary antibodies conjugated
to either fluorescein or Cy5 (Jackson ImmunoResearch Laboratories,
Inc., West Grove, PA) for 60 min at 37 °C. The cells received final
washes for 1 h, and were mounted on slides and visualized using a
Leica TCS NT4D confocal imaging system with a ×40 oil-immersion lens
(Leica, Heidelberg, Germany). During double labeling experiments there was no evidence of bleed-through between channels. Cell images were
processed using Adobe Photoshop software. Images represent typical
staining patterns from multiple experiments.
Rho Activation Assay--
Syndecan-4-null and WT fibroblasts
were seeded on FN-coated 150-mm tissue culture dishes at a
concentration of 1.6 × 106 cells/dish. Following
adhesion and incubation with LPA, as described above, the cells were
processed using the Rho Activation Assay kit (purchased from Upstate
Biotechnology Inc.) according to manufacturer's instructions. Briefly,
cell lysates were incubated with beads conjugated to the Rho-binding
domain of the Rhotekin protein (which only binds GTP-bound Rho (65))
for 45 min at 4 °C. The beads were then washed three times and the
samples were resolved on a 16% SDS-PAGE, transferred to polyvinylidene
difluoride, and incubated with a polyclonal Rho antibody (Upstate
Biotechnology Inc.) overnight at 4 °C. A membrane containing
identical amounts of protein used in the Rho activation assay was
incubated with polyclonal antibodies to Rho (Upstate Biotechnology
Inc.) and actin (Sigma) to serve as loading controls. The blots were
washed, incubated with the appropriate secondary antibody, and exposed to film following treatment with the West Pico enhanced
chemiluminescent reagent (Pierce).
 |
RESULTS |
Cell Adhesion to Fibronectin Increases Phosphorylation of FAK
Tyr397--
Localization of syndecan-4 to focal adhesion
sites is a late event in cell spreading. Significant levels of focal
adhesion-associated syndecan-4 are not apparent until 2 h
post-seeding but levels increase steadily thereafter (18). To address
the contribution of syndecan-4 signaling to FAK Tyr397
phosphorylation, FN-null fibroblasts were seeded onto FN or CBD for
3 h prior to treatment with either activators or inhibitors. FN-null cells were used so as to eliminate any contamination by cell-associated FN and because they have been previously shown to
generate focal adhesions and actin stress fibers in response to
syndecan-4 signaling (24). Initially whole cell lysates were analyzed
for FAK protein expression and general tyrosine phosphorylation. As
shown in Fig. 1A, although the
relative levels of FAK protein remained constant, FN-null cells
exhibited a lower tyrosine phosphorylation level when adherent to the
CBD than when adherent to full-length FN as has been shown previously
(60). To determine whether the difference in phosphotyrosine levels
under the two adhesion conditions included the FAK autophosphorylation
site, a phosphospecific antibody against FAK phosphorylated at
Tyr397 was used. Analysis of the FAK autophosphorylation
site demonstrated that the phosphorylation of Tyr397 is
significantly lower in cells attached to the CBD compared with the
full-length molecule. Reduced phosphorylation under CBD-adherent conditions could be because of either decreased FAK autophosphorylation or increased activity of an endogenous tyrosine phosphatase. To discern
between these two possibilities, FN-null cells seeded on the CBD were
treated with the tyrosine phosphatase inhibitor, sodium vanadate.
Phosphorylation of Tyr397 in CBD-adherent fibroblasts
increased under these conditions to a level comparable with
vanadate-treated FN-adherent fibroblasts (Fig. 1A). General
tyrosine phosphorylation of FAK also increased in FN and CBD-adherent
cells in the presence of vanadate (Fig. 1A). These data
indicate that cell adhesion to full-length FN, compared
with CBD, leads to an accumulation of FAK phosphorylated on
Tyr397. The results suggest that a signal arising from a
non-CBD part of the FN molecule is involved in this process. The data
also suggest that a tyrosine phosphatase may be involved in maintaining a low phosphorylation state of FAK Tyr397 in cells seeded
on the CBD.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
Sodium vanadate and LPA but not PMA increase
FAK Tyr397 phosphorylation in FN-null cells adherent to
CBD. FN-null fibroblasts were seeded onto FN or CBD for 3 h
and treated with: A, 0.5 mM sodium vanadate;
B, 250 nM PMA; or C, 500 ng/ml LPA
for 30 min. Lysates were analyzed for the levels of FAK phosphorylated
at Tyr397 by SDS-PAGE and Western blotting using
phosphospecific anti-FAK Tyr397 polyclonal antibodies.
Lysates were also evaluated for overall expression of FAK and general
tyrosine phosphorylation.
|
|
Protein Kinase C Activity Is Not Involved in Regulating
Phosphorylation of FAK Tyr397--
Protein kinase C
activation precedes cell spreading on FN and its stimulation has been
shown to increase FN-mediated cell adhesion (66, 67). Direct activation
of PKC by the phorbol ester PMA has been shown to stimulate focal
adhesion formation (68) and FAK tyrosine phosphorylation (69).
Recruitment of syndecan-4 to focal adhesions is dependent on PKC (18),
and syndecan-4, in turn, modulates PKC localization and activity
through the binding intermediary phosphatidylinositol bisphosphate (11, 12). As syndecan-4 has no intrinsic catalytic activity, interactions with PKC may serve to initiate syndecan-4-directed signaling events. FN-null cells were seeded on FN or the CBD and subsequently treated with the phorbol ester PMA to induce PKC activation. Tyrosine phosphorylation increased after incubation of both FN- and CBD-adherent cells with PMA but this amplification did not translate to increased FAK Tyr397 phosphorylation under either condition (Fig.
1B). The Me2SO control had no effect. These
results demonstrate that FAK Tyr397 is not phosphorylated
in response to PKC activation and confirm that PKC activation increases
overall tyrosine phosphorylation.
Rho Activation Stimulates Phosphorylation of FAK
Tyr397--
Focal adhesion formation is a
Rho-dependent process (70) and syndecan-4-mediated focal
adhesion formation is inhibited by treatment with C3 exotransferase,
which ADP-ribosylates and inactivates Rho (24). Addition of LPA, which
activates Rho, or constitutively active Rho into serum-starved Swiss
3T3 cells stimulates FAK localization to focal adhesions and also
increases FAK tyrosine phosphorylation levels (55, 56). To determine
whether Rho activation was involved in FAK Tyr397
phosphorylation, FN-null fibroblasts were incubated with LPA following
seeding onto FN or CBD substrates. In the absence of Rho stimulation
general tyrosine phosphorylation and FAK Tyr397
phosphorylation were reduced in CBD-adherent cells when compared with
FN-adherent cells (Fig. 1C and as described above). Rho
stimulation led to an increase in tyrosine phosphorylation of
CBD-adherent cells to a level similar to control FN-adherent cells.
Phosphorylation of Tyr397 also increased in fibroblasts
adherent to the CBD to levels comparable with the FN controls (Fig.
1C). These data indicate that the signaling pathway that
increases FAK Tyr397 phosphorylation in FN-adherent cells
is mediated by the Rho GTPase.
FAK Tyr397 Phosphorylation Is Lower in Syndecan-4-null
Fibroblasts--
Although syndecan-4 ligation has been shown to
stimulate focal adhesion formation in cells adherent to the CBD of FN
(24), Ishiguro et al. (25) recently documented that
fibroblasts derived from syndecan-4-null mice form focal adhesions when
seeded on a FN substrate. They also, however, confirmed that syndecan-4 can stimulate focal adhesion formation by showing that only wild type
cells containing syndecan-4 form focal adhesions when seeded solely on
CBD and subsequently incubated with either the heparin-binding domain
of FN or a syndecan-4 antibody (25). Fibroblasts isolated from
syndecan-4-null mice show reduced migration compared with wild type
controls (26) and overexpression of full-length syndecan-4 core protein
as well as core proteins that contain deletions in the cytoplasmic
region also decrease the rate of migration of CHO-K1 cells (71).
Like the heparan sulfate chains of syndecan-4, those from the
glycosylphosphatidylinositol-linked proteoglycan glypican-1 have been
shown to ligate the Hep-II domain of fibronectin (61). To determine
whether the FAK Tyr397 phosphorylation response
seen in the FN-adherent cells is dependent on the presence of
syndecan-4 and not another cell-surface heparan sulfate proteoglycan,
syndecan-4-null fibroblasts (26) were seeded on full-length FN and
analyzed for phosphorylation of FAK Tyr397. The results
depicted in Fig. 2A show that
the level of phosphorylation of Tyr397 is lower in
syndecan-4-null cells compared with the syndecan-4-WT controls. The
level of Tyr397 phosphorylation is not as low as that of
FN-null cells seeded on CBD and these results are consistent with the
observation that fibroblasts that lack syndecan-4 still spread, form
focal adhesions and stress fibers, and are motile (25, 26). LPA
treatment, to activate the Rho GTPase, increased Tyr397
phosphorylation to that of control syndecan-4-WT cells (Fig. 2A).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 2.
Syndecan-4 acts through Rho to increase
phosphorylation of FAK Tyr397 in syndecan-4-null
fibroblasts. A, syndecan-4-WT and syndecan-4-null
fibroblasts were plated on FN for 3 h and treated with 500 ng/ml
LPA for 60 min. Cells were lysed and analyzed with antibodies to FAK,
-actinin, and phosphospecific antibodies to FAK Tyr397.
B, syndecan-4-null fibroblasts were transiently transfected
with syndecan-4 core protein encoding cDNA (Synd-4) or
vector control (vector). Forty-eight h post-transfection the
cells were plated on FN for 3 h, lysed, and analyzed for protein
expression of syndecan-4, FAK, FAK phosphorylated at
Tyr397, and -actinin.
|
|
Cell-surface expression of syndecan-4 is considered ubiquitous although
its level is lower compared with the expression levels of other family
members (1). To confirm that the absence of syndecan-4 resulted in
diminished phosphorylation of FAK Tyr397, syndecan-4-null
fibroblasts were transiently transfected with a syndecan-4 core protein
encoding cDNA. As shown in Fig. 2B, syndecan-4-null
cells re-expressing syndecan-4 exhibited greater levels of FAK
phosphorylated at Tyr397 then cells transfected with vector
alone. These data indicate that syndecan-4 signaling influences the
level of phosphorylation of FAK Tyr397 and that this
pathway is a Rho-mediated process.
FAK Tyr397 Does Not Localize to Focal Adhesions in
Syndecan-4-null Cells--
The biochemical data suggest that FAK
Tyr397 phosphorylation is altered in the absence of
syndecan-4. To determine whether the subcellular distribution of
autophosphorylated FAK is also affected, immunofluorescent images were
obtained of syndecan-4-WT and syndecan-4-null fibroblasts incubated
with antibodies to FAK, FAK phosphorylated on Tyr397, and
the focal adhesion-associated protein vinculin. Vinculin is considered
a marker of focal adhesion complexes. Both syndecan-4-WT and
syndecan-4-null fibroblasts localize FAK to vinculin-containing focal
adhesion sites when seeded on FN (Fig. 3,
A-B and E-F). Incubation with either LPA (Fig. 3,
C-D and G-H) or PMA (data not shown) did not
alter FAK localization. Syndecan-4-WT cells co-localize FAK
phosphorylated on Tyr397 with vinculin when seeded on a FN
substrate (Fig. 4,
A-B) and this can be inhibited by incubating the
cells with C3 exotransferase that ADP-ribosylates and inactivates Rho
(Fig. 4, E-F). FN-adherent syndecan-4-null cells
generate vinculin-containing focal adhesions (Fig. 4H) but
localization of FAK phosphorylated on Tyr397 could not be
detected (Fig. 4G). Stimulation of the syndecan-4-null cells
with LPA promoted localization of FAK phosphorylated on Tyr397 to focal adhesions (Fig. 4,
I-J), whereas treatment of the fibroblasts with
PMA did not (data not shown). These results mimic the biochemical data
(Figs. 1C and 2A) and suggest that syndecan-4
either promotes the localization of FAK phosphorylated on
Tyr397 to focal adhesion sites or helps to maintain the
autophosphorylated form of FAK in focal adhesions in a
Rho-dependent manner.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 3.
FAK localizes to focal adhesion sites in both
syndecan-4-WT and syndecan-4-null fibroblasts. FN-adherent
syndecan-4-WT (A-D) and syndecan-4-null (E-H) fibroblasts
were treated with LPA (C, D, G, and
H) or medium alone (A, B,
E, and F) and subsequently fixed and stained for FAK
(B, D, F, and H) and
vinculin (A, C, E, and G).
Arrows indicate localization of FAK to vinculin-containing
focal adhesions.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
Syndecan-4-null and C3 exotransferase-treated
syndecan-4-WT cells do not localize FAK phosphorylated on
Tyr397 to focal adhesions. Syndecan-4-WT
(A-F) and syndecan-4-null (G-J) fibroblasts
were seeded on FN, then fixed and stained with antibodies to vinculin
(B, D, F, H, and
J), a marker of focal adhesions, and phosphospecific FAK
Tyr397 (A, C, E,
G, and I) antibodies. Arrows indicate
co-localization of FAK phosphorylated on Tyr397 in
vinculin-containing adhesion sites of WT cells in the absence or
presence of LPA (A-B and
C-D) and in syndecan-4-null cells treated with
LPA (I-J), whereas arrowheads indicate the lack
of phosphorylated FAK Tyr397 in the focal adhesions in
syndecan-4-null cells under control conditions
(G-H). Double arrowheads indicate the
absence of FAK phosphorylated at Tyr397 in the focal
contacts of syndecan-4-WT cells treated with C3 exotransferase
(E-F) to inactivate Rho.
|
|
Rho Activity Is Lower in Syndecan-4-null Cells--
The small
GTPase Rho cycles between an active GTP-bound state and an inactive
GDP-bound state (72-74). Rho activity is regulated through its ability
to bind GTP. Guanine-nucleotide exchange factors catalyze the exchange
of GDP for GTP, whereas GTPase-activating proteins enhance the
endogenous Rho GTPase activity (72, 73). The diminished FAK
Tyr397 phosphorylation in syndecan-4-null cells might be
the result of reduced Rho activity. To ascertain whether the level of
active Rho is affected by the lack of syndecan-4 expression,
syndecan-4-null and syndecan-4-WT fibroblasts were plated onto FN,
treated with LPA, and Rho activity was determined using a pull-down
assay with the Rho-binding domain of Rhotekin (31, 75) that selectively binds GTP-bound Rho (65, 75).
The Rho activity level of syndecan-4-null fibroblasts, as depicted in
Fig. 5, is significantly lower than the
activity level of wild type cells. The lack of Rho stimulation is not
due to a deficiency in the Rho protein as indicated by the Rho blot and the determination that Rho can be activated directly in the
syndecan-4-null cells with LPA (Fig. 5). These data indicate that lack
of syndecan-4 diminishes the basal level of GTP-bound Rho suggesting
that syndecan-4 may positively regulate Rho activation.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 5.
Rho activation is diminished in the absence
of syndecan-4. Syndecan-4-WT and syndecan-4-null fibroblast
lysates were treated with LPA and incubated with beads conjugated to
the Rho-binding domain of Rhotekin. Beads were washed and then
electrophoresed onto SDS-PAGE and blotted for Rho (Rho:GTP). Equal
amounts of lysates were also electrophoresed and blotted for total Rho
and actin as loading controls.
|
|
 |
DISCUSSION |
The heparan sulfate proteoglycan syndecan-4 has two main cellular
functions. It acts as a co-receptor for heparin-binding growth factors
(such as the family of fibroblast growth factors and
heparin-binding vascular endothelial growth factor isoforms) regulating
the ligand-dependent activation of the primary receptor (3). Syndecan-4 also functions, in a Rho-dependent manner, with the 5 1 integrin to
promote the adhesion-dependent formation of actin stress
fibers and focal adhesions (24). Syndecan-4-null fibroblasts will form
focal adhesions and actin stress fibers when plated on a FN substrate
(25, 26). However, the cells are unable to generate focal adhesions
when seeded on the CBD of FN and incubated with either syndecan-4
antibodies or the heparin-binding domain of FN (25). Therefore,
although a compensatory cellular mechanism exists to bypass syndecan-4
deficiency, it is possible to solely evaluate the syndecan-4 signaling pathway.
Transfection of full-length syndecan-4 core protein enhances cell
spreading and focal adhesion formation and decreases cell migration
(71, 76). Interestingly, transfection of cells with syndecan-4
constructs that lack cytoplasmic domains also exhibit decreased cell
migration although they do not form stress fibers or extensive focal
adhesions when seeded on a FN or vitronectin substrate (71).
Fibroblasts generated from mice lacking syndecan-4 also show migration
delays compared with wild type controls (26). The impaired migration in
syndecan-4-null cells may result from the inability of the adhesions to
generate enough tension required for migration or from the inability to
disengage established contacts so that new adhesions may form (29).
Alternatively, although not mutually exclusive from the former,
syndecan-4 may regulate components of a signaling pathway involved in
cell migration and the absence of syndecan-4 disrupts the efficiency
with which the pathway acts.
It has previously been shown that integrin ligation to the CBD of FN
does not induce tyrosine phosphorylation of FAK to the same level as
cells that are ligated to full-length FN (60). We analyzed the
autophosphorylated form of FAK and now demonstrate that FAK
Tyr397 phosphorylation is lower in the absence of the
heparin-binding domain of FN. Incubation of CBD-adherent FN-null cells
with the tyrosine phosphatase inhibitor sodium vanadate augmented the
phosphorylation levels of FAK Tyr397 to that of
vanadate-treated cells seeded on full-length FN suggesting that
syndecan-4 may influence FAK Tyr397 phosphorylation by
regulating the activity of a cellular tyrosine phosphatase. Candidates
for such tyrosine phosphatases are: PTEN (77), PTP-PEST (78), and Shp-2
(79), which have been shown to dephosphorylate FAK in vitro.
Incubation of our cells with the Shp-2 inhibitor calpeptin did not
enhance phosphorylation of FAK Tyr397 (data not shown)
suggesting that under our conditions Shp-2 is not involved in
modulating the phosphorylation state of FAK Tyr397.
Syndecan-4-regulated focal adhesion formation is primarily associated
with two signaling molecules: the serine/threonine kinase PKC and the
small GTPase Rho. Fibroblasts seeded on CBD can be stimulated to
generate actin stress fibers and focal adhesions by incubating the
cells with either PMA (to directly activate PKC) (68) or LPA (to
directly stimulate Rho) (24). It is unclear whether these signaling
molecules collaborate in one signaling pathway or if they work in
parallel but separate pathways. Our study shows that increased
phosphorylation of FAK Tyr397 is associated with the
activation of the Rho pathway and not the PKC pathway, as only LPA and
not PMA increased Tyr397 phosphorylation in our conditions.
Similarly, LPA, but not PMA, treatment also induced the localization of
FAK phosphorylated on Tyr397 to vinculin-containing focal
adhesions in syndecan-4-null cells plated on FN. Therefore, our data
indicate that syndecan-4-mediated FAK phosphorylation occurs only
through a Rho-mediated process and not through a collaboration of both
Rho and PKC stimulation.
PKC activation augmented general tyrosine phosphorylation in
CBD-adherent cells but this stimulation did not translate into increased phosphorylation of FAK Tyr397. The lack of effect
with PMA treatment does not imply that a syndecan-4-PKC pathway does
not exist. Indeed, syndecan-4 and PKC have a close functional
association. PKC recruits syndecan-4 to focal adhesion sites (18) and,
conversely, syndecan-4 binds PKC through the intermediary
phosphatidylinositol bisphosphate (11, 80) and potentiates its activity
(12, 81).
It is possible that PKC promotes focal adhesion formation through an
alternative cell-surface heparan sulfate proteoglycan. Syndecan-4-null
cells will generate actin stress fibers and focal adhesions when seeded
on a combination substrate of CBD and heparin-binding domain FN
fragments, and this effect can be inhibited with the addition of
heparin to the cell medium (25). These data indicate that another
cell-surface heparan sulfate proteoglycan can compensate for the lack
of syndecan-4 to promote focal adhesion and stress fiber formation.
Alternatively, the PKC pathway may be activated following the
association of syndecan-4 with a heparin-binding growth factor receptor. Growth factor ligation (such as fibroblast growth factor-2) may promote the association of syndecan-4 with PKC, leading to its
activation and the subsequent formation of focal adhesions and actin
stress fibers. Syndecan-4 acts as a co-receptor for several
heparin-binding growth factors, regulating the
ligand-dependent activation of the primary receptors (3).
The cytoplasmic domain of syndecan-4 has been implicated in promoting
fibroblast growth factor 2-dependent cell proliferation and
migration (82) and fibroblast growth factor-2 regulates the syndecan-4
dependent activation of PKC (11, 83).
To demonstrate conclusively that the signaling mechanism affecting the
phosphorylation of FAK Tyr397 acts specifically through
syndecan-4, syndecan-4-null fibroblasts were used. The cells were
seeded on a FN substrate as they have been shown to develop focal
adhesions under these conditions. The lack of syndecan-4 expression in
these cells dictates that adhesion to a FN substrate will not stimulate
a syndecan-4 signaling pathway but will activate the unknown
complementary pathway, if it is involved (25). Our experiments reveal
that there is less FAK phosphorylated on Tyr397 in
syndecan-4-null fibroblasts than wild type fibroblasts under basal
conditions and this can be rescued through re-expression of syndecan-4,
demonstrating that syndecan-4 is directly involved in influencing FAK
Tyr397 phosphorylation. The lack of FAK phosphorylated on
Tyr397 in the syndecan-4-null cells was not because of an
inability of Tyr397 to be phosphorylated, as treatment with
LPA or sodium vanadate (data not shown) increased Tyr397
phosphorylation to syndecan-4-WT control levels, but was attributable to a decrease in the levels of active Rho in the cells.
Correspondingly, direct inactivation of Rho using C3 exotransferase
resulted in the loss of FAK phosphorylated at Tyr397 in the
focal adhesions of syndecan-4-WT cells. The syndecan-4-null fibroblasts
still generate vinculin-containing focal complexes so the limited level
of GTP-bound Rho present in the null cells is sufficient to generate
stress fibers and focal adhesions. Incubation of syndecan-4-null
fibroblasts with LPA augmented the level of active Rho, indicating that
the molecule is capable of functioning appropriately but is either not
activated to the same degree as in wild type cells or is unable to
maintain the active state for the "normal" length of time. Rho
activation has been shown to increase FAK phosphorylation (58) and cell
motility (84), whereas inhibition of Rho attenuates both (85, 86).
Although studies have demonstrated that FAK can inhibit Rho activity,
this attenuation occurs during early cell spreading (within 40 min of
cell plating) (31). The cells in our experiments were adherent for
4 h during which Rho activity is higher (75). This is the first
description, to our knowledge, that the heparan sulfate proteoglycan
syndecan-4 influences the level of active Rho in cells.
Rho cycles between an active GTP-bound state and an inactive GDP-bound
state. While active it can bind to its effector molecules: Dia, ROCKs
(Rho kinases), and phosphatidylinositol-4-phosphate 5-kinase to
induce actin polymerization, cell body contraction, and stress fiber
and focal adhesion formation (73, 87). Rho also stimulates cell
motility (88-90) and this may be a function separate to that of
forming focal adhesions and stress fibers (91, 92). Phosphorylation of
FAK at Tyr397 is necessary for optimal cell migration (34,
36, 93). Phosphorylation of FAK on Tyr397 generates a
binding site for SH2-containing proteins. Some of these binding
partners (phosphatidylinositol 3-kinase, Grb7, and Src) increase
cell migration (35, 42, 44, 94, 95) and it may be that FAK serves to
enhance the association of these proteins with their downstream
effectors by binding them within the focal adhesion (95). Indeed,
recent studies have linked Rho activity with the targeting of Src to
focal adhesion sites (96).
As syndecan-4-null cells are deficient in active Rho and phosphorylated
FAK Tyr397 and show impaired cell migration (26) it seems
likely that syndecan-4 signaling is associated with cell migration.
Decreased cell migration is associated with either lack of syndecan-4
expression or by overexpressing full-length syndecan-4 or syndecan-4
containing cytoplasmic deletion mutants (26, 71). That both ends of the spectrum (overexpression of syndecan-4 and lack of syndecan-4) inhibit
cell migration suggests that a homeostasis is generated through
syndecan-4 signaling and a balance may be required for optimal cell
migration. We hypothesize that under conditions in which syndecan-4 is
not ligated (FN-null cells seeded on the CBD or syndecan-4-null cells
seeded on full-length FN) integrin ligation induces the phosphorylation
of FAK Tyr397. Tyrosine phosphatase activity leads to the
subsequent dephosphorylation of this tyrosine residue. The levels of
GTP-bound Rho are also low. This situation is most likely not a static
event but probably encourages the cycling of FAK between a
phosphorylated and nonphosphorylated state on Tyr397.
Ligation of syndecan-4 (whether in FN-null or syndecan-4-WT cells
plated on full-length FN) results in the increased activation of Rho.
This attenuates the tyrosine phosphatase activity causing FAK
Tyr397 to remain phosphorylated longer. The tyrosine
phosphatase activity is not completely inhibited, therefore, cycling
between phosphorylation and dephosphorylation of Tyr397
probably occurs but under a different kinetic. This is pictured diagrammatically in Fig. 6.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 6.
Model of syndecan-4 signaling influencing FAK
phosphorylation of Tyr397. A, ligation of both
integrin and syndecan-4 (syndecan-4-WT cells on FN and FN-null cells on
FN) lead to increased levels of active Rho and diminished activity of a
tyrosine phosphatase. This shifts the equilibrium of FAK
Tyr397 to the phosphorylated state. B, in the
absence of syndecan-4 ligation (syndecan-4-null cells on FN) Rho is not
activated. FAK is phosphorylated on Tyr397 but is
subsequently dephosphorylated through the action of a tyrosine
phosphatase. Under these conditions FAK potentially would be cycling
between the phosphorylated and dephosphorylated state more rapidly than
in the situation described in A. This scenario is also valid
for FN-null cells seeded on CBD.
|
|
 |
ACKNOWLEDGEMENTS |
We thank Hui Su for confocal assistance and
Stefania Saoncella, Tokuro Iwabuchi, and Enzo Calautti for helpful discussions.
 |
FOOTNOTES |
*
This work was supported in part by National Institute of
Health, NICHD Grant HD-37490 and grants from the Cutaneous Biology Research Center through the MGH/Shiseido Company (to P. F. G.) and the Dermatology Foundation Research (to F. D.)The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
This paper is dedicated to the memory of Merton Bernfield who pioneered
the field of syndecan biology.
Supported by National Institutes of Health Postdoctoral Fellowship
F32 HD41235.
§
To whom correspondence should be addressed: Cutaneous Biology
Research Center, MGH-East, Bldg. 149, 13th St.,
Charlestown, MA 02129. Tel.: 617-726-4183; Fax: 617-726-4189; E-mail:
paul.goetinck@cbrc2.mgh.harvard.edu.
Published, JBC Papers in Press, June 26, 2002, DOI 10.1074/jbc.M201283200
 |
ABBREVIATIONS |
The abbreviations used are:
PKC, protein
kinase C;
FAK, focal adhesion kinase;
FN, fibronectin;
CBD, cell-binding domain;
LPA, lysophosphatidic acid;
WT, wild type;
PBS, phosphate-buffered saline;
PMA, phorbol 12-myristate 13-acetate.
 |
REFERENCES |
| 1.
|
Woods, A.
(2001)
J. Clin. Invest.
107,
935-941[Medline]
[Order article via Infotrieve]
|
| 2.
|
Woods, A., Oh, E.-S.,
and Couchman, J. R.
(1998)
Matrix Biol.
17,
477-483[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Carey, D. J.
(1997)
Biochem. J.
327,
1-16[Medline]
[Order article via Infotrieve]
|
| 4.
|
Bernfield, M.,
Gotte, M.,
Park, P. W.,
Reizes, O.,
Fitzgerald, M. L.,
Lincecum, J.,
and Zako, M.
(1999)
Annu. Rev. Biochem.
68,
729-777[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Elenius, K.,
and Jalkanen, M.
(1994)
J. Cell Sci.
107,
2975-2982[Medline]
[Order article via Infotrieve]
|
| 6.
|
Ethell, I. M.,
Hagihara, K.,
Miura, Y.,
Irie, F.,
and Yamaguchi, Y.
(2000)
J. Cell Biol.
151,
53-68[Abstract/Free Full Text]
|
| 7.
|
Hsueh, Y.-P.,
and Sheng, M.
(1999)
J. Neurosci.
19,
7415-7425[Abstract/Free Full Text]
|
| 8.
|
Gao, Y., Li, M.,
Chen, W.,
and Simons, M.
(2000)
J. Cell. Physiol.
184,
373-379[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Grootjans, J. J.,
Zimmermann, P.,
Reekmans, G.,
Smets, A.,
Degeest, G.,
Durr, J.,
and David, G.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
13683-13688[Abstract/Free Full Text]
|
| 10.
|
Cohen, D. J.,
Woods, D. F.,
Marfatia, S. M.,
Walther, Z.,
Chishti, A. H.,
Anderson, J. M.,
and Wood, D. F.
(1998)
J. Cell Biol.
142,
129-138[Abstract/Free Full Text]
|
| 11.
|
Horowitz, A.,
Murakami, M.,
Gao, Y.,
and Simons, M.
(1999)
Biochemistry
38,
15871-15877[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Oh, E.-S.,
Woods, A.,
and Couchman, J. R.
(1997)
J. Biol. Chem.
272,
8133-8136[Abstract/Free Full Text]
|
| 13.
|
Baciu, P. C.,
Saoncella, S.,
Lee, S. H.,
Denhez, F.,
Leuthardt, D.,
and Goetinck, P. F.
(2000)
J. Cell Sci.
113,
315-324[Abstract]
|
| 14.
|
Lebakken, C. S.,
McQuade, K. J.,
and Rapraeger, A. C.
(2000)
Exp. Cell Res.
259,
315-325[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Utani, A.,
Nomizu, M.,
Matsuura, H.,
Kato, K.,
Kobayashi, T.,
Takeda, U.,
Aota, S.,
Nielsen, P. K.,
and Shinkai, H.
(2001)
J. Biol. Chem.
276,
28779-28788[Abstract/Free Full Text]
|
| 16.
|
Woods, A.,
Longley, R. L.,
Tumova, S.,
and Couchman, J. R.
(2000)
Arch. Biochem. Biophys.
374,
66-72[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Woods, A.,
and Couchman, J. R.
(1994)
Mol. Biol. Cell
5,
183-192[Abstract]
|
| 18.
|
Baciu, P. C.,
and Goetinck, P. F.
(1995)
Mol. Biol. Cell
6,
1503-1513[Abstract]
|
| 19.
|
Burridge, K.,
and Chrzanowska-Wodnicka, M.
(1996)
Annu. Rev. Cell Dev. Biol.
12,
463-519[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Zamir, E.,
and Geiger, B.
(2001)
J. Cell Sci.
114,
3583-3590[Medline]
[Order article via Infotrieve]
|
| 21.
|
Petit, V.,
and Thiery, J. P.
(2000)
Biol. Cell
92,
477-494[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Woods, A.,
Couchman, J. R.,
Johansson, S.,
and Hook, M.
(1986)
EMBO J.
5,
665-670[Medline]
[Order article via Infotrieve]
|
| 23.
|
Bloom, L.,
Ingham, K. C.,
and Hynes, R. O.
(1999)
Mol. Biol. Cell
10,
1521-1536[Abstract/Free Full Text]
|
| 24.
|
Saoncella, S.,
Echtermeyer, F.,
Denhez, F.,
Nowlen, J. K.,
Mosher, D. F.,
Robinson, S. D.,
Hynes, R. O.,
and Goetinck, P. F.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2805-2810[Abstract/Free Full Text]
|
| 25.
|
Ishiguro, K.,
Kadomatsu, K.,
Kojima, T.,
Muramatsu, H.,
Tsuzuki, S.,
Nakamura, E.,
Kusugami, K.,
Saito, H.,
and Muramatsu, T.
(2000)
J. Biol. Chem.
275,
5249-5252[Abstract/Free Full Text]
|
| 26.
|
Echtermeyer, F.,
Streit, M.,
Wilcox-Adelman, S.,
Saoncella, S.,
Denhez, F.,
Detmar, M.,
and Goetinck, P.
(2001)
J. Clin. Invest.
107,
R9-R14[Medline]
[Order article via Infotrieve]
|
| 27.
|
Ishiguro, K.,
Kadomatsu, K.,
Kojima, T.,
Muramatsu, H.,
Iwase, M.,
Yoshikai, Y.,
Yanada, M.,
Yamamoto, K.,
Matsushita, T.,
Nishimura, M.,
Kusugami, K.,
Saito, H.,
and Muramatsu, T.
(2001)
J. Biol. Chem.
276,
47483-47488[Abstract/Free Full Text]
|
| 28.
|
Ishiguro, K.,
Kadomatsu, K.,
Kojima, T.,
Muramatsu, H.,
Matsuo, S.,
Kusugami, K.,
Saito, H.,
and Muramatsu, T.
(2001)
Lab. Invest.
81,
509-516[Medline]
[Order article via Infotrieve]
|
| 29.
|
Palecek, S. P.,
Loftus, J. C.,
Ginsberg, M. H.,
Lauffenburger, D. A.,
and Horwitz, A. F.
(1997)
Nature
385,
537-540[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Ilic, D.,
Furuta, Y.,
Kanazawa, S.,
Takeda, N.,
Sobue, K.,
Nakatsuji, N.,
Nomura, S.,
Fujimoto, J.,
Okada, M.,
Yamamoto, T.,
and Aizawa, S.
(1995)
Nature
377,
539-544[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Ren, X. D.,
Kiosses, W. B.,
Sieg, D. J.,
Otey, C. A.,
Schlaepfer, D. D.,
and Schwartz, M. A.
(2000)
J. Cell Sci.
113,
3673-3678[Abstract]
|
| 32.
|
Ilic, D.,
Kanazawa, S.,
Furuta, Y.,
Yamamoto, T.,
and Aizawa, S.
(1996)
Exp. Cell Res.
222,
298-303[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Sieg, D. J.,
Ilic, D.,
Jones, K. C.,
Damsky, C. H.,
Hunter, T.,
and Schlaepfer, D. D.
(1998)
EMBO J.
17,
5933-5947[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Owen, J. D.,
Ruest, P. J.,
Fry, D. W.,
and Hanks, S. K.
(1999)
Mol. Cell. Biol.
19,
4806-4818[Abstract/Free Full Text]
|
| 35.
|
Cary, L. A.,
Chang, J. F.,
and Guan, J.-L.
(1996)
J. Cell Sci.
109,
1787-1794[Abstract]
|
| 36.
|
Sieg, D. J.,
Hauck, C. R.,
and Schlaepfer, D. D.
(1999)
J. Cell Sci.
112,
2677-2691[Abstract]
|
| 37.
|
Zachary, I.
(1997)
Int. J. Biochem. Cell Biol.
29,
929-934[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Schaller, M. D.,
Hildebrand, J. D.,
Shannon, J. D.,
Fox, J. W.,
Vines, R. R.,
and Parsons, J. T.
(1994)
Mol. Cell. Biol.
14,
1680-1688[Abstract/Free Full Text]
|
| 39.
|
Miyamoto, S.,
Teramoto, H.,
Coso, O. A.,
Gutkind, J. S.,
Burbelo, P. D.,
Akiyama, S. K.,
and Yamada, K. M.
(1995)
J. Cell Biol.
131,
791-805[Abstract/Free Full Text]
|
| 40.
|
Otey, C. A.
(1996)
Int. Rev. Cytol.
167,
161-183[Medline]
[Order article via Infotrieve]
|
| 41.
|
Schlaepfer, D. D.,
Hauck, C. R.,
and Sieg, D. J.
(1999)
Prog. Biophys. Mol. Biol.
71,
435-478[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Chen, H.-C.,
Appeddu, P. A.,
Isoda, H.,
and Guan, J.-L.
(1996)
J. Biol. Chem.
271,
26329-26334[Abstract/Free Full Text]
|
| 43.
|
Zhang, X.,
Chattopadhyay, A., Ji, Q.-S.,
Owen, J. D.,
Ruest, P. J.,
Carpenter, G.,
and Hanks, S. K.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
9021-9026[Abstract/Free Full Text]
|
| 44.
|
Han, D. C.,
and Guan, J.-L.
(1999)
J. Biol. Chem.
274,
24425-24430[Abstract/Free Full Text]
|
| 45.
|
Schlaepfer, D. D.,
Jones, K. C.,
and Hunter, T.
(1998)
Mol. Cell. Biol.
18,
2571-2585[Abstract/Free Full Text]
|
| 46.
|
Tamura, M., Gu, J.,
Danen, E. H.,
Takino, T.,
Miyamoto, S.,
and Yamada, K. M.
(1999)
J. Biol. Chem.
274,
20693-20703[Abstract/Free Full Text]
|
| 47.
|
Schaller, M. D.
(2001)
Biochim. Biophys. Acta
1540,
1-21[Medline]
[Order article via Infotrieve]
|
| 48.
|
Calalb, M. B.,
Polte, T. R.,
and Hanks, S. K.
(1995)
Mol. Cell. Biol.
15,
954-963[Abstract]
|
| 49.
|
Calalb, M. B.,
Zhang, X.,
Polte, T. R.,
and Hanks, S. K.
(1996)
Biochem. Biophys. Res. Commun.
228,
662-668[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Schlaepfer, D. D.,
Hanks, S. K.,
Hunter, T.,
and van der Geer, P.
(1994)
Nature
372,
786-791[Medline]
[Order article via Infotrieve]
|
| 51.
|
Schlaepfer, D. D.,
and Hunter, T.
(1996)
Mol. Cell. Biol.
16,
5623-5633[Abstract]
|
| 52.
|
Kumagai, N.,
Morii, N.,
Fujisawa, K.,
Yoshimasa, T.,
Nakao, K.,
and Narumiya, S.
(1993)
FEBS Lett.
329,
273-276[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Chrzanowska-Wodnicka, M.,
and Burridge, K.
(1994)
J. Cell Sci.
107,
3643-3654[Abstract]
|
| 54.
|
Ridley, A. J.,
and Hall, A.
(1994)
EMBO J.
13,
2600-2610[Medline]
[Order article via Infotrieve]
|
| 55.
|
Barry, S. T.,
and Critchley, D. R.
(1994)
J. Cell Sci.
107,
2033-2045[Abstract]
|
| 56.
|
Flinn, H. M.,
and Ridley, A. J.
(1996)
J. Cell Sci.
109,
1133-1141[Abstract]
|
| 57.
|
Rodriguez-Fernandez, J. L.,
and Rozengurt, E.
(1998)
J. Biol. Chem.
273,
19321-19328[Abstract/Free Full Text]
|
| 58.
|
Clark, E. A.,
King, W. G.,
Brugge, J. S.,
Symons, M.,
and Hynes, R. O.
(1998)
J. Cell Biol.
142,
573-586[Abstract/Free Full Text]
|
| 59.
|
Burridge, K.,
Turner, C. E.,
and Romer, L. H.
(1992)
J. Cell Biol.
119,
893-903[Abstract/Free Full Text]
|
| 60.
|
Jeong, J.,
Han, I.,
Lim, Y.,
Kim, J.,
Park, I.,
Woods, A.,
Couchman, J. R.,
and Oh, E. S.
(2001)
Biochem. J.
356,
531-537[CrossRef][Medline]
[Order article via Infotrieve]
|
| 61.
|
Tumova, S.,
Woods, A.,
and Couchman, J. R.
(2000)
J. Biol. Chem.
275,
9410-9417[Abstract/Free Full Text]
|
| 62.
|
Rapraeger, A. C.,
and Ott, V. L.
(1998)
J. Biol. Chem.
273,
35291-35298[Abstract/Free Full Text]
|
| 63.
|
Xu, F.,
and Zhao, Z. J.
(2001)
Exp. Cell Res.
262,
49-58[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Small, J. V.,
and Celis, J. E.
(1978)
J. Cell Sci.
31,
393-409[Abstract]
|
| 65.
|
Reid, T.,
Furuyashiki, T.,
Ishizaki, T.,
Watanabe, G.,
Watanabe, N.,
Fujisawa, K.,
Morii, N.,
Madaule, P.,
and Narumiya, S.
(1996)
J. Biol. Chem.
271,
13556-13560[Abstract/Free Full Text]
|
| 66.
|
Vuori, K.,
and Ruoslahti, E.
(1993)
J. Biol. Chem.
268,
21459-21462[Abstract/Free Full Text]
|
| 67.
|
Brown, P. J.
(1988)
Biochem. Biophys. Res. Commun.
155,
603-607[CrossRef][Medline]
[Order article via Infotrieve]
|
| 68.
|
Woods, A.,
and Courchman, J. R.
(1992)
J. Cell Sci.
101,
277-290[Abstract/Free Full Text]
|
| 69.
|
Bruce-Staskal, P. J.,
and Bouton, A. H.
(2001)
Exp. Cell Res.
264,
296-306[CrossRef][Medline]
[Order article via Infotrieve]
|
| 70.
|
Ridley, A. J.,
and Hall, A.
(1992)
Cell
70,
389-399[CrossRef][Medline]
[Order article via Infotrieve]
|
| 71.
|
Longley, R. L.,
Woods, A.,
Fleetwood, A.,
Cowling, G. J.,
Gallagher, J. T.,
and Couchman, J. R.
(1999)
J. Cell Sci.
112,
3421-3431[Abstract]
|
| 72.
|
Zohn, I. M.,
Campbell, S. L.,
Khosravi-Far, R.,
Rossman, K. L.,
and Der, C. J.
(1998)
Oncogene
17,
1415-1438[CrossRef][Medline]
[Order article via Infotrieve]
|
| 73.
|
Ridley, A. J.
(2001)
J. Cell Sci.
114,
2713-2722[Abstract/Free Full Text]
|
| 74.
|
Mackay, D. J.,
and Hall, A.
(1998)
J. Biol. Chem.
273,
20685-20688[Free Full Text]
|
| 75.
|
Ren, X.-D.,
Kiosses, W. B.,
and Schwartz, M. A.
(1999)
EMBO J.
18,
578-585[CrossRef][Medline]
[Order article via Infotrieve]
|
| 76.
|
Echtermeyer, F.,
Baciu, P. C.,
Saoncella, S., Ge, Y.,
and Goetinck, P. F.
(1999)
J. Cell Sci.
112,
3433-3441[Abstract]
|
| 77.
|
Tamura, M., Gu, J.,
Matsumoto, K.,
Aota, S.-I.,
Parsons, R.,
and Yamada, K. M.
(1998)
Science
280,
1614-1617[Abstract/Free Full Text]
|
| 78.
|
Angers-Loustau, A.,
Cote, J.-F.,
Charest, A.,
Dowbenko, D.,
Spencer, S.,
Lasky, L. A.,
and Trembley, M. L.
(1999)
J. Cell Biol.
144,
1019-1031[Abstract/Free Full Text]
|
| 79.
|
Manes, S.,
Mira, E.,
Gomez-Mouton, C.,
Zhao, Z. J.,
Lacalle, R. A.,
and Martinez, A. C.
(1999)
Mol. Cell. Biol.
19,
3125-3135[Abstract/Free Full Text]
|
| 80.
|
Oh, E. S.,
Woods, A.,
Lim, S. T.,
Theibert, A. W.,
and Couchman, J. R.
(1998)
J. Biol. Chem.
273,
10624-10629[Abstract/Free Full Text]
|
| 81.
|
Oh, E.-S.,
Woods, A.,
and Couchman, J. R.
(1997)
J. Biol. Chem.
272,
11805-11811[Abstract/Free Full Text]
|
| 82.
|
Volk, R.,
Schwartz, J. J., Li, J.,
Rosenberg, R. D.,
and Simons, M.
(1999)
J. Biol. Chem.
274,
24417-24424[Abstract/Free Full Text]
|
| 83.
|
Horowitz, A.,
and Simons, M.
(1998)
J. Biol. Chem.
273,
10914-10918[Abstract/Free Full Text]
|
| 84.
|
Matsumoto, Y.,
Tanaka, K.,
Harimaya, K.,
Nakatani, F.,
Matsuda, S.,
and Iwamoto, Y.
(2001)
Jpn. J. Cancer Res.
92,
429-438[CrossRef]
|
| 85.
|
Bobak, D.,
Moorman, J.,
Guanzon, A.,
Gilmer, L.,
and Hahn, C.
(1997)
Oncogene
15,
2179-2189[CrossRef][Medline]
[Order article via Infotrieve]
|
| 86.
|
Imamura, F.,
Mukai, M.,
Ayaki, M.,
and Akedo, H.
(2000)
Jpn. J. Cancer Res.
91,
811-816[CrossRef]
|
| 87.
|
Geiger, B.,
and Bershadsky, A.
(2001)
Curr. Opin. Cell Biol.
13,
584-592[CrossRef][Medline]
[Order article via Infotrieve]
|
| 88.
|
Yoshioka, K.,
Matsumura, F.,
Akedo, H.,
and Itoh, K.
(1998)
J. Biol. Chem.
273,
5146-5154[Abstract/Free Full Text]
|
| 89.
|
Takaishi, K.,
Kikuchi, A.,
Kuroda, S.,
Kotani, K.,
Sasaki, T.,
and Takai, Y.
(1993)
Mol. Cell. Biol.
13,
72-79[Abstract/Free Full Text]
|
| 90.
|
Stasia, M. J.,
Jouan, A.,
Bourmeyster, N.,
Boquet, P.,
and Vignais, P. V.
(1991)
Biochem. Biophys. Res. Commun.
180,
615-622[CrossRef][Medline]
[Order article via Infotrieve]
|
| 91.
|
Nabi, I. R.
(1999)
J. Cell Sci.
112,
1803-1811[Abstract]
|
| 92.
|
Machesky, L. M.,
and Hall, A.
(1997)
J. Cell Biol.
138,
913-926[Abstract/Free Full Text]
|
| 93.
|
Wang, H. B.,
Dembo, M.,
Hanks, S. K.,
and Wang, Y.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
11295-11300[Abstract/Free Full Text]
|
| 94.
|
Reiske, H. R.,
Kao, S. C.,
Cary, L. A.,
Guan, J. L.,
Lai, J. F.,
and Chen, H. C.
(1999)
J. Biol. Chem.
274,
12361-12366[Abstract/Free Full Text]
|
| 95.
|
Shen, T. L.,
and Guan, J. L.
(2001)
FEBS Lett.
499,
176-181[CrossRef][Medline]
[Order article via Infotrieve]
|
| 96.
|
Timpson, P.,
Jones, G. E.,
Frame, M. C.,
and Brunton, V. G.
(2001)
Curr. Biol.
11,
1836-1846[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. A. Williams and J. E. Schwarzbauer
A Shared Mechanism of Adhesion Modulation for Tenascin-C and Fibulin-1
Mol. Biol. Cell,
February 1, 2009;
20(4):
1141 - 1149.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. Bass, M. R. Morgan, K. A. Roach, J. Settleman, A. B. Goryachev, and M. J. Humphries
p190RhoGAP is the convergence point of adhesion signals from {alpha}5{beta}1 integrin and syndecan-4
J. Cell Biol.,
October 21, 2008;
181(6):
1013 - 1026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Telci, Z. Wang, X. Li, E. A. M. Verderio, M. J. Humphries, M. Baccarini, H. Basaga, and M. Griffin
Fibronectin-Tissue Transglutaminase Matrix Rescues RGD-impaired Cell Adhesion through Syndecan-4 and {beta}1 Integrin Co-signaling
J. Biol. Chem.,
July 25, 2008;
283(30):
20937 - 20947.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Shintani, Y. Fukumoto, N. Chaika, R. Svoboda, M. J. Wheelock, and K. R. Johnson
Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1
J. Cell Biol.,
March 24, 2008;
180(6):
1277 - 1289.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. Bass, K. A. Roach, M. R. Morgan, Z. Mostafavi-Pour, T. Schoen, T. Muramatsu, U. Mayer, C. Ballestrem, J. P. Spatz, and M. J. Humphries
Syndecan-4-dependent Rac1 regulation determines directional migration in response to the extracellular matrix
J. Cell Biol.,
May 7, 2007;
177(3):
527 - 538.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Dovas, A. Yoneda, and J. R. Couchman
PKC{alpha}-dependent activation of RhoA by syndecan-4 during focal adhesion formation
J. Cell Sci.,
July 1, 2006;
119(13):
2837 - 2846.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Chen, X. Shi-wen, J. van Beek, L. Kennedy, M. McLeod, E. A. Renzoni, G. Bou-Gharios, S. Wilcox-Adelman, P. F. Goetinck, M. Eastwood, et al.
Matrix Contraction by Dermal Fibroblasts Requires Transforming Growth Factor-{beta}/Activin-Linked Kinase 5, Heparan Sulfate-Containing Proteoglycans, and MEK/ERK: Insights into Pathological Scarring in Chronic Fibrotic Disease
Am. J. Pathol.,
December 1, 2005;
167(6):
1699 - 1711.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Wang, R. A. F. Clark, D. F. Mosher, and X.-D. Ren
Fibronectin's Central Cell-binding Domain Supports Focal Adhesion Formation and Rho Signal Transduction
J. Biol. Chem.,
August 5, 2005;
280(31):
28803 - 28810.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Tkachenko, J. M. Rhodes, and M. Simons
Syndecans: New Kids on the Signaling Block
Circ. Res.,
March 18, 2005;
96(5):
488 - 500.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Chen, D. J. Abraham, X. Shi-wen, J. D. Pearson, C. M. Black, K. M. Lyons, and A. Leask
CCN2 (Connective Tissue Growth Factor) Promotes Fibroblast Adhesion to Fibronectin
Mol. Biol. Cell,
December 1, 2004;
15(12):
5635 - 5646.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. S. Midwood, L. V. Valenick, H. C. Hsia, and J. E. Schwarzbauer
Coregulation of Fibronectin Signaling and Matrix Contraction by Tenascin-C and Syndecan-4
Mol. Biol. Cell,
December 1, 2004;
15(12):
5670 - 5677.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Saoncella, E. Calautti, W. Neveu, and P. F. Goetinck
Syndecan-4 Regulates ATF-2 Transcriptional Activity in a Rac1-dependent Manner
J. Biol. Chem.,
November 5, 2004;
279(45):
47172 - 47176.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D.D.W. Cornelison, S. A. Wilcox-Adelman, P. F. Goetinck, H. Rauvala, A. C. Rapraeger, and B. B. Olwin
Essential and separable roles for Syndecan-3 and Syndecan-4 in skeletal muscle development and regeneration
Genes & Dev.,
September 15, 2004;
18(18):
2231 - 2236.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ishida, G. Hirai, K. Murakami, T. Teruya, S. Simizu, M. Sodeoka, and H. Osada
Structure-based design of a selective heparanase inhibitor as an antimetastatic agent
Mol. Cancer Ther.,
September 1, 2004;
3(9):
1069 - 1077.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Stephens, P. Grenard, P. Aeschlimann, M. Langley, E. Blain, R. Errington, D. Kipling, D. Thomas, and D. Aeschlimann
Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses
J. Cell Sci.,
July 1, 2004;
117(15):
3389 - 3403.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Nakahara, E. Miyoshi, K. Noda, S. Ihara, J. Gu, K. Honke, H. Inohara, T. Kubo, and N. Taniguchi
Involvement of oligosaccharide changes in {alpha}5{beta}1 integrin in a cisplatin-resistant human squamous cell carcinoma cell line
Mol. Cancer Ther.,
November 1, 2003;
2(11):
1207 - 1214.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Wierzbicka-Patynowski and J. E. Schwarzbauer
The ins and outs of fibronectin matrix assembly
J. Cell Sci.,
August 15, 2003;
116(16):
3269 - 3276.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. K. Thodeti, R. Albrechtsen, M. Grauslund, M. Asmar, C. Larsson, Y. Takada, A. M. Mercurio, J. R. Couchman, and U. M. Wewer
ADAM12/Syndecan-4 Signaling Promotes beta 1 Integrin-dependent Cell Spreading through Protein Kinase Calpha and RhoA
J. Biol. Chem.,
March 7, 2003;
278(11):
9576 - 9584.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|